ClinicalTrials.gg
CompletedNCT01786668Updated Jun 10, 2016Results posted

Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

A Phase 2 interventional study of Tofacitinib 2 mg and Tofacitinib 5 mg in Ankylosing Spondylitis, sponsored by Pfizer. Completed at 67 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-06-10.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
208
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Spondylitis, Ankylosing by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Spondylitis, Ankylosing · Pfizer.

Enrollment
8th of 18
208 · median 129
Started
2013
with 1 other
Phase 2
2 of 34
none open now
Registered
25th of 34
by date

Among the 34 studies in Spondylitis, Ankylosing by Pfizer, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2013, is one of 2 in phase 2, and was the 25th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

1 of the 34 studies in Spondylitis, Ankylosing by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Spondylitis, Ankylosing by Pfizer, or all of them as a file.
02

Study summary

This is the first study of oral tofacitinib in adults with active ankylosing spondylitis. It is designed to obtain information on the efficacy and safety of 3 different doses of tofacitinib.

03

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • Ankylosing Spondylitis
  • Spondylitis
  • Ankylosing
  • Spondyloarthritis
  • Spondyloarthropathy
  • Oral preparation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of Ankylosing Spondylitis
  • Has active disease despite concurrent nonsteroidal anti-inflammatory drugs (NSAIDs) treatment or is intolerant to NSAIDs

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating females
  • Currently receiving or previous use of a Tumor Necrosis Factor (TNF) inhibitor or any biological agent
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
208 participants (actual)

Study arms

  • Experimental
    Tofacitinib 2 mg

    Drug: Tofacitinib 2 mg

  • Experimental
    Tofacitinib 5 mg

    Drug: Tofacitinib 5 mg

  • Experimental
    Tofacitinib 10 mg

    Drug: Tofacitinib 10 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks

  • 4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks

  • 4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks

  • DrugPlacebo

    4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving 20 Percent (%) Improvement in Assessment of SpondyloArthritis International Society (ASAS) Score (ASAS 20) at Week 12

    The primary analysis of this outcome measure was performed using the Emax model. Clinical response to treatment was assessed according to ASAS20 criteria. ASAS20 responder had improvement of greater than or equal to (≥) 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and less than or equal to (≤)1 unit in the remaining domain. The domains are: Patient's Global Assessment of Disease Activity, spinal pain, function and inflammation (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Missing data were handled by nonresponsive (NRI)/ last observation carried forward (LOCF). Missing values due to a subject dropping out from the study were handled by setting the ASAS20 value to NRI. The LOCF approach was applied to missing components, if just some of the components of the ASAS20 were missing.

    Time frame: Week 12

  2. Percentage of Participants Achieving ASAS20 at Week 12

    The supportive analysis of this outcome measure was performed using the normal approximation for two proportions. Clinical response to treatment was assessed according to ASAS20 criteria. ASAS20 responder had improvement of ≥ 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and ≤1 unit in the remaining domain. The domains are: Patient's Global Assessment of Disease Activity, spinal pain, function and inflammation (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Missing data were handled by NRI/LOCF. Missing values due to a subject dropping out from the study were handled by setting the ASAS20 value to NRI. The LOCF approach was applied to missing components, if just some of the components of the ASAS20 were missing.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Percentage of Participants Achieving 20% Improvement in ASAS Score at Weeks 2, 4 and 8

    Clinical response to treatment was assessed according to ASAS20 criteria. ASAS20 responder had improvement of ≥ 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and ≤1 unit in the remaining domain. The domains are: Patient's Global Assessment of Disease Activity, spinal pain, function and inflammation (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Missing data were handled by NRI/LOCF. Missing values due to a subject dropping out from the study were handled by setting the ASAS20 value to NRI. The LOCF approach was applied to missing components, if just some of the components of the ASAS20 were missing.

    Time frame: Baseline, Week 2, Week 4, Week 8

  2. Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score of the Sacroiliac (SI) Joints at Week 12

    SPARCC scoring consists of assessing six SI joint MRI image coronal slices representing the largest proportion of the synovial compartment of the SI joints for edema. The maximum score per slice was 2 and 12 for all 6 slices. The total minimum and maximum score for all SI joints across 6 slices is 0 to 72 and higher scores indicate more inflammation. A negative change from baseline indicates improvement. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.

    Time frame: Baseline, Week 12

  3. Change From Baseline in SPARCC MRI Index of Disease Activity Score of the Spine at Week 12

    SPARCC scoring of the magnetic resonance imaging (MRI) of the spine consists of assessing six disco-vertebral units (DVU) with 3 consecutive sagittal slices at each DVU. The minimum and maximum SPARCC score for all 6 DVUs is 0 to 108, with higher scores indicating more damage. A negative change from baseline indicates improvement. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.

    Time frame: Baseline, Week 12

  4. Change From Baseline in Modified Berlin Ankylosing Spondylitis Spine Magnetic Resonance Imaging Activity Score (ASspiMRI) of the Spine at Week 12

    Berlin modification of the ASspiMRI is a measure of acute lesion as determined by short-tau inversion recovery (STIR) sequences. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1), defined as the region between 2 virtual lines through the middle of each vertebra, were scored in a single dimension, which is represented the highest level of inflammation in that particular DVU. Total spine ASspiMRI scores can range from 0-69 with higher scores indicating more disease activity. A negative change from baseline indicates improvement. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.

    Time frame: Baseline, Week 12

  5. Percentage of Participants Achieving 40% Improvement in ASAS Score at Weeks 2, 4, 8 and 12

    ASAS 40 is defined as ≥40% and absolute change of ≥2 units in at least 3 domains on a 0-10 scale (0=no disease activity, 10=high disease activity), and no worsening in the remaining domain. Missing data were handled by NRI/LOCF.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12

  6. Percentage of Participants Achieving ASAS5/6 Response at Weeks 2, 4, 8 and 12

    ASAS5/6 consists of 6 domains: the 4 used in ASAS20 (Patient's Global Assessment of Disease Activity, spinal pain, function, inflammation plus spinal mobility and an acute phase reactant, C Reactive Protein (CRP). ASAS 5/6 is defined as ≥20% improvement in at least 5 domains and no worsening in the remaining domain. Missing data were handled by NRI/LOCF.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12

  7. Change From Baseline of Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein ASDAS(CRP) at Weeks 2, 4, 8 and 12

    The ASDAS(CRP) is a derived score that uses back pain, duration of morning stiffness, Patient's Global Assessment of their disease and peripheral pain/swelling. The formula used for calculating the ASDAS (CRP)is: 0.12 x Back Pain + 0.06 x Duration of Morning Stiffness + 0.11 x Patient Global + 0.07 x Peripheral Pain/Swelling + 0.58 x Ln(CRP+1). The calculated score can be from 0 to no defined upper limit. A negative number indicates a reduction in the score which indicates decrease in disease activity.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12

  8. Percentage of Participants With ASDAS Clinically Important Improvement at Weeks 2, 4, 8 and 12

    The ASDAS clinically important improvement was calculated from the ASDAS data. The ASDAS clinically important improvement is defined as change (decrease) from baseline of ≥1.1 units. Missing data were handled by NRI/LOCF.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12

  9. Percentage of Participants With ASDAS Major Improvement at Weeks 2, 4, 8 and 12

    The ASDAS major improvement was calculated from the ASDAS data. The ASDAS major improvement was defined as change (decrease) from baseline of ≥2.0 units. Missing data were handled by NRI/LOCF.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12

  10. Percentage of Participants Achieving ASDAS Inactive Disease at Weeks 2, 4, 8 and 12

    The ASDAS inactive disease was calculated from the ASDAS data. The ASDAS inactive disease was defined as ASDAS \<1.3 units. Missing data were handled by NRI/LOCF.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12

  11. Change From Baseline in BASDAI Total Score at Week 2, 4, 8 and 12

    BASDAI is a validated self-assessment tool used to determine disease activity in participant with Ankylosing Spondylitis. Utilizing a Numerical Rating Scale (NRS) of 0-10 (0 = none and 10 = very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The BASDAI score is calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions (Q)1-4. This score is then divided by 5. BASDAI=Q1+Q2+Q3+Q4+\[Q5+Q6/2\]/5. The final BASDAI score averages the individual assessments for a final score range of 0-10. Negative values indicate improvement.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12

  12. Percentage of Participants Achieving a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)50 Response at Weeks 2, 4, 8 and 12

    BASDAI is a validated self-assessment tool used to determine disease activity in participant with Ankylosing Spondylitis. Utilizing a Numerical Rating Scale (NRS) of 0-10 (0 = none and 10 = very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The BASDAI score is calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions (Q)1-4. This score is then divided by 5. The final BASDAI score range from 0-10. A positive response was defined as a 50% improvement in the BASDAI from baseline.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12

  13. Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, 8 and 12

    BASFI is a validated self-assessment tool that determines the degree of physical functional limitation in Ankylosing Spondylitis. Utilizing a Numerical Rating Scale (NRS) of 0-10 (0=easy, 10=impossible), participants answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions with lower scores indicating better physical function. The higher the negative value the better the improvement.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12

  14. Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Weeks 2, 4, 8 and 12

    BASMI is an objective measure of spinal mobility and was completed by a blinded assessor. The BASMI score is composed of 5 clinical measures: cervical rotation, intermalleolar distance, modified Schober's test, lateral flexion and tragus to wall distance. The derived score used the average of the 5 assessments on a scale of 0-10 scale with higher scores indicating more impairment of spinal mobility. BASMI was analyzed using the linear function method. The higher the negative value the better the improvement.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12

  15. Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Weeks 4, 8 and 12

    Assessment of enthesitis of 13 sites was performed in the following, 1st costochondral joint left and right, 7th costochondral joint left and right, posterior superior iliac spine left and right, anterior superior iliac spine left and right, iliac crest left and right, 5th lumbar spinous process and proximal insertion of Achilles tendon left and right. Each site was graded for the presence (1) and absence (0) of tenderness yielding total MASES ranging from 0 (no tenderness) to 13 (worst possible score; severe tenderness).

    Time frame: Baseline, Week 4, Week 8, Week 12

  16. Extra-Articular Involvement From Specific Ankylosing Spondylitis Medical History

    Participants were assessed at Baseline, Week 12 and Week 16 (Follow-up) to determine if they had specific Ankylosing Spondylitis medical history or changes in specific Ankylosing Spondylitis medical history which included: Inflammatory Bowel Disease (IBD), Peripheral Articular Involvement (PAI; as assessed by swollen joint count), psoriasis (PSO) and uveitis (UVE).

    Time frame: Baseline, Week 12 and Follow-up

  17. Change From Baseline of Total Swollen Joint Count at Weeks 2, 4 8 and 12

    This assessment was performed by the blinded assessor using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints) for determination of the total number of swollen joints. Forty-four joints were assessed for swelling on left and right side and included the following: sternoclaviculars, acromioclaviculars, shoulders, elbows, wrists, metacarpophalangeals (I, II, III, IV, V), thumb interphalangeal, proximal interphalangeals (II, III, IV, V), knees, ankles, and metatarsophalangeals (I, II, III, IV, V). Artificial joints were not assessed. A negative change means improvement.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12

  18. Change From Baseline of Mean Spinal Mobility (Chest Expansion) at Week 2, 4, 8 and 12

    Chest expansion, measured in centimeters (cm), is defined as the difference in the thoracic circumference during full expiration versus full inspiration. This was measured at the 4th intercostal space. The difference between maximal inspiration and expiration of the two attempts was recorded. The better of the two attempts was used to calculate chest expansion. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12

  19. Change From Baseline to Week 12 in Short-Form-36 Health Survey (SF-36) Physical and Mental Health Scores at Week 12

    SF-36 is a standardized survey evaluating 8 aspects of functional health and wellbeing: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (0=no functioning, 100=highest level of functioning). Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.

    Time frame: Baseline, Week 12

  20. Change From Baseline in EuroQol EQ-5D Health State Profile (EQ-5D) Utility Score at Week 12

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of single utility score. Health state profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression; Scale range 1 to 3 (1=better health state \[no problems\], 3=worst health state \[confined to bed\]).

    Time frame: Baseline, Week 12

  21. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Weeks 2, 4, 8 and 12

    FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).

    Time frame: Baseline, Week 2, Week 4, Week 8, Week 12

07

Results

Posted Jun 10, 2016

Participant flow

Participant flow — Overall Study
MilestoneTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Started52525251
Completed51514747
Not completed1154
Withdrew: Adverse event0112
Withdrew: Withdrawal by subject0031
Withdrew: Pregnancy0001
Withdrew: Lost to follow-up1010

Outcome measures

PrimaryPercentage of Participants Achieving 20 Percent (%) Improvement in Assessment of SpondyloArthritis International Society (ASAS) Score (ASAS 20) at Week 12

The primary analysis of this outcome measure was performed using the Emax model. Clinical response to treatment was assessed according to ASAS20 criteria. ASAS20 responder had improvement of greater than or equal to (≥) 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and less than or equal to (≤)1 unit in the remaining domain. The domains are: Patient's Global Assessment of Disease Activity, spinal pain, function and inflammation (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Missing data were handled by nonresponsive (NRI)/ last observation carried forward (LOCF). Missing values due to a subject dropping out from the study were handled by setting the ASAS20 value to NRI. The LOCF approach was applied to missing components, if just some of the components of the ASAS20 were missing.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving 20 Percent (%) Improvement in Assessment of SpondyloArthritis International Society (ASAS) Score (ASAS 20) at Week 12
Percentage of participantsTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants Achieving 20 Percent (%) Improvement in Assessment of SpondyloArthritis International Society (ASAS) Score (ASAS 20) at Week 1256.063.067.440.1
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Emax Model · Risk difference (rd): 15.8 · 95% CI 5.0 to 30.3
  • Tofacitinib 5 mg BID vs Placebo BID · Emax Model · Risk difference (rd): 22.9 · 95% CI 8.4 to 37.7
  • Tofacitinib 10 mg BID vs Placebo BID · Emax Model · Risk difference (rd): 27.3 · 95% CI 10.7 to 43.4
PrimaryPercentage of Participants Achieving ASAS20 at Week 12

The supportive analysis of this outcome measure was performed using the normal approximation for two proportions. Clinical response to treatment was assessed according to ASAS20 criteria. ASAS20 responder had improvement of ≥ 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and ≤1 unit in the remaining domain. The domains are: Patient's Global Assessment of Disease Activity, spinal pain, function and inflammation (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Missing data were handled by NRI/LOCF. Missing values due to a subject dropping out from the study were handled by setting the ASAS20 value to NRI. The LOCF approach was applied to missing components, if just some of the components of the ASAS20 were missing.

Time frame:
Baseline, Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ASAS20 at Week 12
Percentage of participantsTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Percentage of Participants Achieving ASAS20 at Week 1251.9280.7755.7741.18
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.271 · Risk difference (rd): 10.75 · 95% CI -8.41 to 29.90
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = <0.001 · Risk difference (rd): 39.59 · 95% CI 22.35 to 56.83
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.134 · Risk difference (rd): 14.59 · 95% CI -4.50 to 33.69
SecondaryPercentage of Participants Achieving 20% Improvement in ASAS Score at Weeks 2, 4 and 8

Clinical response to treatment was assessed according to ASAS20 criteria. ASAS20 responder had improvement of ≥ 20% and ≥1 unit in at least 3 domains (on a scale of 0 \[least\] to 10 \[worst\]) and no worsening of ≥20% and ≤1 unit in the remaining domain. The domains are: Patient's Global Assessment of Disease Activity, spinal pain, function and inflammation (from Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\]). Missing data were handled by NRI/LOCF. Missing values due to a subject dropping out from the study were handled by setting the ASAS20 value to NRI. The LOCF approach was applied to missing components, if just some of the components of the ASAS20 were missing.

Time frame:
Baseline, Week 2, Week 4, Week 8
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving 20% Improvement in ASAS Score at Weeks 2, 4 and 8
Percentage of participantsTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 2 (n=21,17,18,14)40.3832.6934.6227.45
Week 4 (n=25,29,25,17)48.0855.7748.0833.33
Week 8 (n=30, 37, 28, 22)57.6971.1553.8543.14
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.162 · Risk difference (rd): 12.93 · 95% CI -5.17 to 31.04
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.561 · Risk difference (rd): 5.24 · 95% CI -12.44 to 22.92
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.430 · Risk difference (rd): 7.16 · 95% CI -10.65 to 24.97
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.123 · Risk difference (rd): 14.74 · 95% CI -4.01 to 33.50
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.019 · Risk difference (rd): 22.44 · 95% CI 3.74 to 41.13
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.123 · Risk difference (rd): 14.74 · 95% CI -4.01 to 33.50
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.135 · Risk difference (rd): 14.56 · 95% CI -4.55 to 33.66
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.003 · Risk difference (rd): 28.02 · 95% CI 9.68 to 46.36
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.274 · Risk difference (rd): 10.71 · 95% CI -8.48 to 29.90
SecondaryChange From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score of the Sacroiliac (SI) Joints at Week 12

SPARCC scoring consists of assessing six SI joint MRI image coronal slices representing the largest proportion of the synovial compartment of the SI joints for edema. The maximum score per slice was 2 and 12 for all 6 slices. The total minimum and maximum score for all SI joints across 6 slices is 0 to 72 and higher scores indicate more inflammation. A negative change from baseline indicates improvement. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score of the Sacroiliac (SI) Joints at Week 12
Units on a scaleTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score of the Sacroiliac (SI) Joints at Week 12-1.70 ± 0.779-3.15 ± 0.788-3.55 ± 0.795-0.81 ± 0.806
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · ANCOVA · p = 0.427 · Mean difference (final values): -0.89 · 95% CI -3.11 to 1.32
  • Tofacitinib 5 mg BID vs Placebo BID · ANCOVA · p = 0.039 · Mean difference (final values): -2.35 · 95% CI -4.58 to -0.12
  • Tofacitinib 10 mg BID vs Placebo BID · ANCOVA · p = 0.016 · Mean difference (final values): -2.74 · 95% CI -4.97 to -0.51
SecondaryChange From Baseline in SPARCC MRI Index of Disease Activity Score of the Spine at Week 12

SPARCC scoring of the magnetic resonance imaging (MRI) of the spine consists of assessing six disco-vertebral units (DVU) with 3 consecutive sagittal slices at each DVU. The minimum and maximum SPARCC score for all 6 DVUs is 0 to 108, with higher scores indicating more damage. A negative change from baseline indicates improvement. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in SPARCC MRI Index of Disease Activity Score of the Spine at Week 12
Units on a scaleTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Change From Baseline in SPARCC MRI Index of Disease Activity Score of the Spine at Week 12-3.09 ± 1.061-5.51 ± 1.063-6.57 ± 1.073-0.09 ± 1.085
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · ANCOVA · p = 0.050 · Mean difference (final values): -3.00 · 95% CI -5.99 to -0.00
  • Tofacitinib 5 mg BID vs Placebo BID · ANCOVA · p = <0.001 · Mean difference (final values): -5.42 · 95% CI -8.42 to -2.42
  • Tofacitinib 10 mg BID vs Placebo BID · ANCOVA · p = <0.001 · Mean difference (final values): -6.47 · 95% CI -9.48 to -3.46
SecondaryChange From Baseline in Modified Berlin Ankylosing Spondylitis Spine Magnetic Resonance Imaging Activity Score (ASspiMRI) of the Spine at Week 12

Berlin modification of the ASspiMRI is a measure of acute lesion as determined by short-tau inversion recovery (STIR) sequences. All 23 disco-vertebral units (DVU) of the spine (from C2 to S1), defined as the region between 2 virtual lines through the middle of each vertebra, were scored in a single dimension, which is represented the highest level of inflammation in that particular DVU. Total spine ASspiMRI scores can range from 0-69 with higher scores indicating more disease activity. A negative change from baseline indicates improvement. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Modified Berlin Ankylosing Spondylitis Spine Magnetic Resonance Imaging Activity Score (ASspiMRI) of the Spine at Week 12
Units on a scaleTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Change From Baseline in Modified Berlin Ankylosing Spondylitis Spine Magnetic Resonance Imaging Activity Score (ASspiMRI) of the Spine at Week 12-1.05 ± 0.364-2.22 ± 0.364-2.13 ± 0.368-0.41 ± 0.372
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · ANCOVA · p = 0.221 · Mean difference (final values): -0.64 · 95% CI -1.66 to 0.39
  • Tofacitinib 5 mg BID vs Placebo BID · ANCOVA · p = <0.001 · Mean difference (final values): -1.80 · 95% CI -2.83 to -0.78
  • Tofacitinib 10 mg BID vs Placebo BID · ANCOVA · p = 0.001 · Mean difference (final values): -1.71 · 95% CI -2.75 to -0.68
SecondaryPercentage of Participants Achieving 40% Improvement in ASAS Score at Weeks 2, 4, 8 and 12

ASAS 40 is defined as ≥40% and absolute change of ≥2 units in at least 3 domains on a 0-10 scale (0=no disease activity, 10=high disease activity), and no worsening in the remaining domain. Missing data were handled by NRI/LOCF.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving 40% Improvement in ASAS Score at Weeks 2, 4, 8 and 12
Percentage of participantsTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 2 (n=7, 7, 9, 8)13.4613.4617.3115.69
Week 4 (n=15, 17, 11, 8)28.8532.6921.1515.69
Week 8 (n=15, 18, 19, 14)28.8534.6236.5427.45
Week 12 (n=22, 24, 20, 10)42.3146.1538.4619.61
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.749 · Risk difference (rd): -2.22 · 95% CI -15.85 to 11.40
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.749 · Risk difference (rd): -2.22 · 95% CI -15.85 to 11.40
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.824 · Risk difference (rd): 1.62 · 95% CI -12.71 to 15.95
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.104 · Risk difference (rd): 13.16 · 95% CI -2.69 to 29.01
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.040 · Risk difference (rd): 17.01 · 95% CI 0.81 to 33.20
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.473 · Risk difference (rd): 5.47 · 95% CI -9.46 to 20.40
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.875 · Risk difference (rd): 1.40 · 95% CI -15.97 to 18.76
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.430 · Risk difference (rd): 7.16 · 95% CI -10.65 to 24.97
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.320 · Risk difference (rd): 9.09 · 95% CI -8.84 to 27.01
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.010 · Risk difference (rd): 22.70 · 95% CI 5.41 to 39.99
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.003 · Risk difference (rd): 26.55 · 95% CI 9.16 to 43.93
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.031 · Risk difference (rd): 18.85 · 95% CI 1.72 to 35.99
SecondaryPercentage of Participants Achieving ASAS5/6 Response at Weeks 2, 4, 8 and 12

ASAS5/6 consists of 6 domains: the 4 used in ASAS20 (Patient's Global Assessment of Disease Activity, spinal pain, function, inflammation plus spinal mobility and an acute phase reactant, C Reactive Protein (CRP). ASAS 5/6 is defined as ≥20% improvement in at least 5 domains and no worsening in the remaining domain. Missing data were handled by NRI/LOCF.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ASAS5/6 Response at Weeks 2, 4, 8 and 12
Percentage of participantsTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 2 (n=12, 7, 11, 4)23.0813.4621.157.84
Week 4 (n=10, 16, 15, 4)19.2330.7728.857.84
Week 8 (n=11, 22, 15, 5)21.1542.3128.859.80
Week 12 (n=10, 26, 20, 8)19.2350.0038.4615.69
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.028 · Risk difference (rd): 15.23 · 95% CI 1.61 to 28.86
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.353 · Risk difference (rd): 5.62 · 95% CI -6.23 to 17.47
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.050 · Risk difference (rd): 13.31 · 95% CI -0.02 to 26.64
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.086 · Risk difference (rd): 11.39 · 95% CI -1.62 to 24.39
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.002 · Risk difference (rd): 22.93 · 95% CI 8.37 to 37.48
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.004 · Risk difference (rd): 21.00 · 95% CI 6.65 to 35.36
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.106 · Risk difference (rd): 11.35 · 95% CI -2.43 to 25.13
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = <0.001 · Risk difference (rd): 32.50 · 95% CI 16.79 to 48.22
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.012 · Risk difference (rd): 19.04 · 95% CI 4.27 to 33.81
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.635 · Risk difference (rd): 3.54 · 95% CI -11.10 to 18.19
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = <0.001 · Risk difference (rd): 34.31 · 95% CI 17.45 to 51.18
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.007 · Risk difference (rd): 22.78 · 95% CI 6.21 to 39.34
SecondaryChange From Baseline of Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein ASDAS(CRP) at Weeks 2, 4, 8 and 12

The ASDAS(CRP) is a derived score that uses back pain, duration of morning stiffness, Patient's Global Assessment of their disease and peripheral pain/swelling. The formula used for calculating the ASDAS (CRP)is: 0.12 x Back Pain + 0.06 x Duration of Morning Stiffness + 0.11 x Patient Global + 0.07 x Peripheral Pain/Swelling + 0.58 x Ln(CRP+1). The calculated score can be from 0 to no defined upper limit. A negative number indicates a reduction in the score which indicates decrease in disease activity.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline of Ankylosing Spondylitis Disease Activity Score Using C-Reactive Protein ASDAS(CRP) at Weeks 2, 4, 8 and 12
Units on a scaleTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 2-0.68 ± 0.096-1.00 ± 0.096-0.97 ± 0.096-0.50 ± 0.097
Week 4-1.01 ± 0.099-1.20 ± 0.099-1.17 ± 0.099-0.58 ± 0.100
Week 8-1.08 ± 0.111-1.36 ± 0.111-1.32 ± 0.112-0.73 ± 0.112
Week 12-1.23 ± 0.119-1.41 ± 0.119-1.37 ± 0.121-0.68 ± 0.123
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.175 · Mean difference (final values): -0.19 · 95% CI -0.46 to 0.08Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.51 · 95% CI -0.77 to -0.24Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.47 · 95% CI -0.74 to -0.20Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.003 · Mean difference (final values): -0.43 · 95% CI -0.70 to -0.15Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.62 · 95% CI -0.90 to -0.34Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.59 · 95% CI -0.86 to -0.31Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.026 · Mean difference (final values): -0.35 · 95% CI -0.66 to -0.04Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.63 · 95% CI -0.94 to -0.32Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.59 · 95% CI -0.90 to -0.27Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.002 · Mean difference (final values): -0.55 · 95% CI -0.89 to -0.21Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.73 · 95% CI -1.07 to -0.39Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -0.69 · 95% CI -1.03 to -0.35Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
SecondaryPercentage of Participants With ASDAS Clinically Important Improvement at Weeks 2, 4, 8 and 12

The ASDAS clinically important improvement was calculated from the ASDAS data. The ASDAS clinically important improvement is defined as change (decrease) from baseline of ≥1.1 units. Missing data were handled by NRI/LOCF.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With ASDAS Clinically Important Improvement at Weeks 2, 4, 8 and 12
Percentage of participantsTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 2 (n=14, 25, 21, 8)26.9248.0840.3815.69
Week4 (n=22, 30, 27, 10)42.3157.6951.9219.61
Week 8 (n=23, 31, 31, 15)44.2359.6259.6229.41
Week 12 (n=27, 33, 29, 14)51.9263.4655.7727.45
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.159 · Risk difference (rd): 11.24 · 95% CI -4.41 to 26.89
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = <0.001 · Risk difference (rd): 32.39 · 95% CI 15.54 to 49.24
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.004 · Risk difference (rd): 24.70 · 95% CI 8.04 to 41.36
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.010 · Risk difference (rd): 22.70 · 95% CI 5.41 to 39.99
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = <0.001 · Risk difference (rd): 38.08 · 95% CI 20.79 to 55.38
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = <0.001 · Risk difference (rd): 32.32 · 95% CI 14.90 to 49.73
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.114 · Risk difference (rd): 14.82 · 95% CI -3.58 to 33.22
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.001 · Risk difference (rd): 30.20 · 95% CI 11.92 to 48.49
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.001 · Risk difference (rd): 30.20 · 95% CI 11.92 to 48.49
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.009 · Risk difference (rd): 24.47 · 95% CI 6.18 to 42.76
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = <0.001 · Risk difference (rd): 36.01 · 95% CI 18.09 to 53.94
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.002 · Risk difference (rd): 28.32 · 95% CI 10.09 to 46.55
SecondaryPercentage of Participants With ASDAS Major Improvement at Weeks 2, 4, 8 and 12

The ASDAS major improvement was calculated from the ASDAS data. The ASDAS major improvement was defined as change (decrease) from baseline of ≥2.0 units. Missing data were handled by NRI/LOCF.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With ASDAS Major Improvement at Weeks 2, 4, 8 and 12
Percentage of participantsTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 2 (n=4, 4, 4, 1)7.697.697.691.96
Week 4 (n=6, 6, 8, 3)11.5411.5415.385.88
Week 8 (n=6, 14, 12, 5)11.5426.9223.089.80
Week 12 (n=10, 12, 13, 6)19.2323.0825.0011.76
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.170 · Risk difference (rd): 5.73 · 95% CI -2.45 to 13.91
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.170 · Risk difference (rd): 5.73 · 95% CI -2.45 to 13.91
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.170 · Risk difference (rd): 5.73 · 95% CI -2.45 to 13.91
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.306 · Risk difference (rd): 5.66 · 95% CI -5.17 to 16.48
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.306 · Risk difference (rd): 5.66 · 95% CI -5.17 to 16.48
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.113 · Risk difference (rd): 9.50 · 95% CI -2.24 to 21.24
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.775 · Risk difference (rd): 1.73 · 95% CI -10.18 to 13.65
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.021 · Risk difference (rd): 17.12 · 95% CI 2.56 to 31.68
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.064 · Risk difference (rd): 13.27 · 95% CI -0.79 to 27.34
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.292 · Risk difference (rd): 7.47 · 95% CI -6.42 to 21.36
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.125 · Risk difference (rd): 11.31 · 95% CI -3.16 to 25.78
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.078 · Risk difference (rd): 13.24 · 95% CI -1.49 to 27.96
SecondaryPercentage of Participants Achieving ASDAS Inactive Disease at Weeks 2, 4, 8 and 12

The ASDAS inactive disease was calculated from the ASDAS data. The ASDAS inactive disease was defined as ASDAS \<1.3 units. Missing data were handled by NRI/LOCF.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ASDAS Inactive Disease at Weeks 2, 4, 8 and 12
Percentage of participantsTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 2 (n=1, 1, 1, 0)1.921.921.920.00
Week 4 (n=1, 3, 4, 1)1.925.777.691.96
Week 8 (n=3, 1, 5, 1)5.771.929.621.96
Week 12 (n=7, 7, 8, 4)13.4613.4615.387.84
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.313 · Risk difference (rd): 1.92 · 95% CI -1.81 to 5.66
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.313 · Risk difference (rd): 1.92 · 95% CI -1.81 to 5.66
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.313 · Risk difference (rd): 1.92 · 95% CI -1.81 to 5.66
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.989 · Risk difference (rd): -0.04 · 95% CI -5.37 to 5.29
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.313 · Risk difference (rd): 3.81 · 95% CI -3.58 to 11.20
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.170 · Risk difference (rd): 5.73 · 95% CI -2.45 to 13.91
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.313 · Risk difference (rd): 3.81 · 95% CI -3.58 to 11.20
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.989 · Mean difference (final values): -0.04 · 95% CI -5.37 to 5.29
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.091 · Risk difference (rd): 7.65 · 95% CI -1.22 to 16.52
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.353 · Risk difference (rd): 5.62 · 95% CI -6.23 to 17.47
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.353 · Risk difference (rd): 5.62 · 95% CI -6.23 to 17.47
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.228 · Risk difference (rd): 7.54 · 95% CI -4.73 to 19.81
SecondaryChange From Baseline in BASDAI Total Score at Week 2, 4, 8 and 12

BASDAI is a validated self-assessment tool used to determine disease activity in participant with Ankylosing Spondylitis. Utilizing a Numerical Rating Scale (NRS) of 0-10 (0 = none and 10 = very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The BASDAI score is calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions (Q)1-4. This score is then divided by 5. BASDAI=Q1+Q2+Q3+Q4+\[Q5+Q6/2\]/5. The final BASDAI score averages the individual assessments for a final score range of 0-10. Negative values indicate improvement.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in BASDAI Total Score at Week 2, 4, 8 and 12
Units on a scaleTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 2-1.45 ± 0.219-1.53 ± 0.217-1.24 ± 0.219-1.42 ± 0.219
Week 4-1.90 ± 0.242-1.93 ± 0.240-1.84 ± 0.242-1.60 ± 0.243
Week 8-2.16 ± 0.268-2.39 ± 0.267-2.35 ± 0.271-1.87 ± 0.271
Week 12-2.75 ± 0.277-2.88 ± 0.276-2.68 ± 0.281-1.85 ± 0.283
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.926 · Mean difference (final values): -0.03 · 95% CI -0.64 to 0.58Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.718 · Mean difference (final values): -0.11 · 95% CI -0.72 to 0.50Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.570 · Mean difference (final values): 0.18 · 95% CI -0.43 to 0.79Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.384 · Mean difference (final values): -0.30 · 95% CI -0.97 to 0.38Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.334 · Mean difference (final values): -0.33 · 95% CI -1.00 to 0.34Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.474 · Mean difference (final values): -0.25 · 95% CI -0.92 to 0.43Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.445 · Mean difference (final values): -0.29 · 95% CI -1.04 to 0.46Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.174 · Mean difference (final values): -0.52 · 95% CI -1.27 to 0.23Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.217 · Mean difference (final values): -0.47 · 95% CI -1.23 to 0.28Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.024 · Mean difference (final values): -0.90 · 95% CI -1.69 to -0.12Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.010 · Mean difference (final values): -1.03 · 95% CI -1.81 to -0.24Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.038 · Mean difference (final values): -0.83 · 95% CI -1.62 to -0.04Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
SecondaryPercentage of Participants Achieving a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)50 Response at Weeks 2, 4, 8 and 12

BASDAI is a validated self-assessment tool used to determine disease activity in participant with Ankylosing Spondylitis. Utilizing a Numerical Rating Scale (NRS) of 0-10 (0 = none and 10 = very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The BASDAI score is calculated by computing the mean of questions 5 and 6 and adding it to the sum of questions (Q)1-4. This score is then divided by 5. The final BASDAI score range from 0-10. A positive response was defined as a 50% improvement in the BASDAI from baseline.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)50 Response at Weeks 2, 4, 8 and 12
Percentage of participantsTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 2 (n=6, 11, 7, 8)11.54 (2.92 to 20.61)21.1513.4615.69
Week 4 (n=15, 12, 15, 11)28.8523.0828.8521.57
Week 8 (n=18, 17, 21, 14)34.6232.6940.3827.45
Week 12 (n=24, 22, 22, 12)46.1542.3142.3123.53
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.539 · Risk difference (rd): -4.15 · 95% CI -17.38 to 9.08
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.473 · Risk difference (rd): 5.47 · 95% CI -9.46 to 20.40
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.749 · Risk difference (rd): -2.22 · 95% CI -15.85 to 11.40
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.393 · Risk difference (rd): 7.28 · 95% CI -9.43 to 23.98
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.854 · Risk difference (rd): 1.51 · 95% CI -14.57 to 17.59
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.393 · Risk difference (rd): 7.28 · 95% CI -9.43 to 23.98
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.430 · Risk difference (rd): 7.16 · 95% CI -10.65 to 24.97
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.561 · Risk difference (rd): 5.24 · 95% CI -12.44 to 22.92
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.162 · Risk difference (rd): 12.93 · 95% CI -5.17 to 31.04
  • Tofacitinib 2 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.013 · Risk difference (rd): 22.62 · 95% CI 4.76 to 40.49
  • Tofacitinib 5 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.038 · Risk difference (rd): 18.78 · 95% CI 1.01 to 36.55
  • Tofacitinib 10 mg BID vs Placebo BID · Normal approximation for two proportions · p = 0.038 · Risk difference (rd): 18.78 · 95% CI 1.01 to 36.55
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, 8 and 12

BASFI is a validated self-assessment tool that determines the degree of physical functional limitation in Ankylosing Spondylitis. Utilizing a Numerical Rating Scale (NRS) of 0-10 (0=easy, 10=impossible), participants answered 10 questions assessing their ability in completing normal daily activities or physically demanding activities. The BASFI score is a mean score of the 10 questions with lower scores indicating better physical function. The higher the negative value the better the improvement.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Weeks 2, 4, 8 and 12
Units on a scaleTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 2-1.12 ± 0.192-1.16 ± 0.191-0.86 ± 0.192-0.74 ± 0.192
Week 4-1.36 ± 0.210-1.61 ± 0.208-1.32 ± 0.210-1.02 ± 0.210
Week 8-1.61 ± 0.247-2.07 ± 0.246-1.72 ± 0.249-1.38 ± 0.249
Week 12-1.90 ± 0.261-2.39 ± 0.260-2.24 ± 0.264-1.43 ± 0.266
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.164 · Mean difference (final values): -0.38 · 95% CI -0.92 to 0.16Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.129 · Mean difference (final values): -0.41 · 95% CI -0.95 to 0.12Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.660 · Mean difference (final values): -0.12 · 95% CI -0.66 to 0.42Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.256 · Mean difference (final values): -0.34 · 95% CI -0.92 to 0.25Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.048 · Mean difference (final values): -0.59 · 95% CI -1.17 to -0.00Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.318 · Mean difference (final values): -0.30 · 95% CI -0.88 to 0.29Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.522 · Mean difference (final values): -0.22 · 95% CI -0.92 to 0.47Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.050 · Mean difference (final values): -0.69 · 95% CI -1.38 to 0.00Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.337 · Mean difference (final values): -0.34 · 95% CI -1.03 to 0.36Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.214 · Mean difference (final values): -0.47 · 95% CI -1.20 to 0.27Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.011 · Mean difference (final values): -0.96 · 95% CI -1.69 to -0.22Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.031 · Mean difference (final values): -0.81 · 95% CI -1.55 to -0.08Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
SecondaryChange From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Weeks 2, 4, 8 and 12

BASMI is an objective measure of spinal mobility and was completed by a blinded assessor. The BASMI score is composed of 5 clinical measures: cervical rotation, intermalleolar distance, modified Schober's test, lateral flexion and tragus to wall distance. The derived score used the average of the 5 assessments on a scale of 0-10 scale with higher scores indicating more impairment of spinal mobility. BASMI was analyzed using the linear function method. The higher the negative value the better the improvement.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Weeks 2, 4, 8 and 12
Units on a scaleTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 2-0.09 ± 0.075-0.24 ± 0.075-0.22 ± 0.075-0.09 ± 0.075
Week 4-0.15 ± 0.083-0.24 ± 0.083-0.26 ± 0.084-0.14 ± 0.084
Week 8-0.34 ± 0.095-0.40 ± 0.095-0.48 ± 0.096-0.19 ± 0.096
Week 12-0.33 ± 0.109-0.42 ± 0.109-0.55 ± 0.111-0.16 ± 0.112
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.982 · Mean difference (final values): 0.00 · 95% CI -0.21 to 0.21Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.151 · Mean difference (final values): -0.15 · 95% CI -0.36 to 0.06Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.205 · Mean difference (final values): -0.13 · 95% CI -0.34 to 0.07Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.898 · Mean difference (final values): -0.02 · 95% CI -0.25 to 0.22Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.370 · Mean difference (final values): -0.11 · 95% CI -0.34 to 0.13Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.288 · Mean difference (final values): -0.13 · 95% CI -0.36 to 0.11Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.242 · Mean difference (final values): -0.16 · 95% CI -0.42 to 0.11Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.120 · Mean difference (final values): -0.21 · 95% CI -0.48 to 0.06Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.031 · Mean difference (final values): -0.30 · 95% CI -0.56 to -0.03Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.280 · Mean difference (final values): -0.17 · 95% CI -0.48 to 0.14Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.099 · Mean difference (final values): -0.26 · 95% CI -0.57 to 0.05Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.014 · Mean difference (final values): -0.39 · 95% CI -0.70 to -0.08Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Weeks 4, 8 and 12

Assessment of enthesitis of 13 sites was performed in the following, 1st costochondral joint left and right, 7th costochondral joint left and right, posterior superior iliac spine left and right, anterior superior iliac spine left and right, iliac crest left and right, 5th lumbar spinous process and proximal insertion of Achilles tendon left and right. Each site was graded for the presence (1) and absence (0) of tenderness yielding total MASES ranging from 0 (no tenderness) to 13 (worst possible score; severe tenderness).

Time frame:
Baseline, Week 4, Week 8, Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Weeks 4, 8 and 12
Units on a scaleTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 4-0.16 ± 0.272-0.93 ± 0.271-0.89 ± 0.274-0.11 ± 0.275
Week 8-0.79 ± 0.289-1.19 ± 0.289-0.97 ± 0.295-0.54 ± 0.292
Week 12-0.66 ± 0.259-1.37 ± 0.259-1.24 ± 0.263-0.34 ± 0.265
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.895 · Mean difference (final values): -0.05 · 95% CI -0.81 to 0.71Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.033 · Mean difference (final values): -0.83 · 95% CI -1.59 to -0.07Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.044 · Mean difference (final values): -0.79 · 95% CI -1.55 to -0.02Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.530 · Mean difference (final values): -0.26 · 95% CI -1.07 to 0.55Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.114 · Mean difference (final values): -0.65 · 95% CI -1.46 to 0.16Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.297 · Mean difference (final values): -0.43 · 95% CI -1.25 to 0.38Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.377 · Mean difference (final values): -0.33 · 95% CI -1.06 to 0.40Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.006 · Mean difference (final values): -1.04 · 95% CI -1.77 to -0.31Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.017 · Mean difference (final values): -0.90 · 95% CI -1.64 to -0.17Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
SecondaryExtra-Articular Involvement From Specific Ankylosing Spondylitis Medical History

Participants were assessed at Baseline, Week 12 and Week 16 (Follow-up) to determine if they had specific Ankylosing Spondylitis medical history or changes in specific Ankylosing Spondylitis medical history which included: Inflammatory Bowel Disease (IBD), Peripheral Articular Involvement (PAI; as assessed by swollen joint count), psoriasis (PSO) and uveitis (UVE).

Time frame:
Baseline, Week 12 and Follow-up
Reported as:
Number · Percentage of Participants
Extra-Articular Involvement From Specific Ankylosing Spondylitis Medical History
Percentage of ParticipantsTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
IBD: Never: Baseline (n=6, 9, 6, 4)10088.9100100
IBD: Past But Not Active: Baseline (n=6, 9, 6, 4)0000
IBD: Currently Active: Baseline (n=6, 9, 6, 4)011.100
IBD: New Condition: Baseline (n=6, 9, 6, 4)0000
IBD: Never: Week 4 (n=4, 7, 3, 2)100100100100
IBD: Past But Not Active: Week 4 (n=4, 7, 3, 2)0000
IBD: Currently Active: Week 4 (n=4, 7, 3, 2)0000
IBD: New Condition: Week 4 (n=4, 7, 3, 2)0000
IBD: Never: Week 8 (n=2, 6, 2, 4)100100100100
IBD: Past But Not Active: Week 8 (n=2, 6, 2, 4)0000
IBD: Currently Active: Week 8 (n=2, 6, 2, 4)0000
IBD: New Condition: Week 8 (n=2, 6, 2, 4)0000
IBD: Never: Week 12 (n=5, 6, 2, 3)100100100100
IBD: Past But Not Active: Week 12 (n=5, 6, 2, 3)0000
IBD: Currently Active: Week 12 (n=5, 6, 2, 3)0000
IBD: New Condition: Week 12 (n=5, 6, 2, 3)0000
IBD: Never: Follow-up (n=3, 6, 4, 2)100100100100
IBD: Past But Not Active: Follow-up (n=3, 6, 4, 2)0000
IBD: Currently Active: Follow-up (n=3, 6, 4, 2)0000
IBD: New Condition: Follow-up (n=3, 6, 4, 2)0000
PAI: Never: Baseline (n=6, 9, 6, 4)33.344.4025.0
PAI: Past But Not Active: Baseline (n=6, 9, 6, 4)0016.70
PAI: Currently Active: Baseline (n=6, 9, 6, 4)66.744.466.775.0
PAI: New condition: Baseline (n=6, 9, 6, 4)011.116.70
PAI: Never: Week 4 (n=4, 7, 3, 2)028.600
PAI: Past But Not Active: Week 4 (n=4, 7, 3, 2)014.333.30
PAI: Currently Active: Week 4 (n=4, 7, 3, 2)10057.166.7100
PAI: New condition: Week 4 (n=4, 7, 3, 2)0000
PAI: Never: Week 8 (n=2, 6, 2, 4)050.000
PAI: Past But Not Active: Week 8 (n=2, 6, 2, 4)0050.00
PAI: Currently Active: Week 8 (n=2, 6, 2, 4)10050.050.0100
PAI: New Condition: Week 8 (n=2, 6, 2, 4)0000
PAI: Never: Week 12 (n=5, 5, 2, 3)20.040.000
PAI: Past But Not Active: Week 12 (n=5, 5, 2, 3)0000
PAI: Currently Active: Week 12 (n=5, 5, 2, 3)40.060.0100100
PAI: New Condition: Week 12 (n=5, 5, 2, 3)40.0000
PAI: Never: Follow-up (n=3, 6, 4, 2)050.025.00
PAI: Past But Not Active: Follow-up (n=3, 6, 4, 2)0025.00
PAI: Currently Active: Follow-up (n=3, 6, 4, 2)66.750.050.0100
PAI: New Condition: Follow-up (n=3, 6, 4, 2)33.3000
PSO: Never: Baseline (n=6, 9, 6, 4)10088.983.375.0
PSO: Past But Not Active: Baseline (n=6, 9, 6, 4)0000
PSO: Currently Active: Baseline (n=6, 9, 6, 4)011.116.725.0
PSO: New Condition: Baseline (n=6, 9, 6, 4)0000
PSO: Never: Week 4 (n=4, 7, 3, 2)10085.766.7100
PSO: Past But Not Active: Week 4 (n=4, 7, 3, 2)0000
PSO: Currently Active: Week 4 (n=4, 7, 3, 2)014.333.30
PSO: New Condition: Week 4 (n=4, 7, 3, 2)0000
PSO: Never: Week 8 (n=2, 6, 2, 4)10083.350.0100
PSO: Past But Not Active: Week 8 (n=2, 6, 2, 4)0000
PSO: Currently Active: Week 8 (n=2, 6, 2, 4)016.750.00
PSO: New Condition: Week 8 (n=2, 6, 2, 4)0000
PSO: Never: Week 12 (n=5, 6, 2, 3)80.083.3100100
PSO: Past But Not Active: Week 12 (n=5, 6, 2, 3)20.0000
PSO: Currently Active: Week 12 (n=5, 6, 2, 3)016.700
PSO: New Condition: Week 12 (n=5, 6, 2, 3)0000
PSO: Never: Follow-up (n=3, 6, 4, 2)10083.3100100
PSO: Past But Not Active: Follow-up (n=3, 6, 4, 2)0000
PSO: Currently Active: Follow-up (n=3, 6, 4, 2)016.700
PSO: New Condition: Follow-up (n=3, 6, 4, 2)0000
UVE: Never: Baseline (n=6, 9, 6, 4)50.055.683.3100
UVE: Past But Not Active: Baseline (n=6, 9, 6, 4)16.733.300
UVE: Currently Active: Baseline (n=6, 9, 6, 4)33.311.116.70
UVE: New Condition: Baseline (n=6, 9, 6, 4)0000
UVE: Never: Week 4 (n=4, 7, 3, 2)75.071.466.7100
UVE: Past But Not Active: Week 4 (n=4, 7, 3, 2)25.028.633.30
UVE: Currently Active: Week 4 (n=4, 7, 3, 2)0000
UVE: New Condition: Week 4 (n=4, 7, 3, 2)0000
UVE: Never: Week 8 (n=2, 6, 2, 4)10050.050.0100
UVE: Past But Not Active: Week 8 (n=2, 6, 2, 4)050.050.00
UVE: Currenly Active: Week 8 (n=2, 6, 2, 4)0000
UVE: New Condition: Week 8 (n=2, 6, 2, 4)0000
UVE: Never: Week 12 (n=5, 6, 2, 3)40.066.750.0100
UVE: Past But Not Active: Week 12 (n=5, 6, 2, 3)60.033.350.00
UVE: Currently Active: Week 12 (n=5, 6, 2, 3)0000
UVE: New Condition: Week 12 (n=5, 6, 2, 3)0000
UVE: Never: Follow-up (n=3, 6, 4, 2)10050.050.0100
UVE: Past But Not Active: Follow-up (n=3, 6, 4, 2)033.325.00
UVE: Currently Active: Follow-up (n=3, 6, 4, 2)016.700
UVE: New Condition: Follow-up (n=3, 6, 4, 2)0025.00
SecondaryChange From Baseline of Total Swollen Joint Count at Weeks 2, 4 8 and 12

This assessment was performed by the blinded assessor using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints) for determination of the total number of swollen joints. Forty-four joints were assessed for swelling on left and right side and included the following: sternoclaviculars, acromioclaviculars, shoulders, elbows, wrists, metacarpophalangeals (I, II, III, IV, V), thumb interphalangeal, proximal interphalangeals (II, III, IV, V), knees, ankles, and metatarsophalangeals (I, II, III, IV, V). Artificial joints were not assessed. A negative change means improvement.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12
Reported as:
Least squares mean · Swollen Joints
Change From Baseline of Total Swollen Joint Count at Weeks 2, 4 8 and 12
Swollen JointsTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 2-0.53 ± 0.2930.23 ± 0.291-1.20 ± 0.292-0.43 ± 0.293
Week 4-0.87 ± 0.260-0.57 ± 0.259-1.23 ± 0.260-0.86 ± 0.261
Week 8-1.02 ± 0.442-0.98 ± 0.442-1.28 ± 0.451-0.60 ± 0.448
Week 12-0.87 ± 0.362-0.79 ± 0.362-1.40 ± 0.368-0.99 ± 0.373
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.800 · Mean difference (final values): -0.11 · 95% CI -0.92 to 0.71Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.113 · Mean difference (final values): 0.66 · 95% CI -0.16 to 1.47Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.064 · Mean difference (final values): -0.77 · 95% CI -1.59 to 0.05Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.972 · Mean difference (final values): -0.01 · 95% CI -0.74 to 0.71
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.440 · Mean difference (final values): 0.28 · 95% CI -0.44 to 1.01Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.311 · Mean difference (final values): -0.37 · 95% CI -1.10 to 0.35Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.501 · Mean difference (final values): -0.42 · 95% CI -1.66 to 0.82Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.543 · Mean difference (final values): -0.38 · 95% CI -1.63 to 0.86Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.287 · Mean difference (final values): -0.68 · 95% CI -1.93 to 0.57Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.820 · Mean difference (final values): 0.12 · 95% CI -0.91 to 1.14Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.711 · Mean difference (final values): 0.19 · 95% CI -0.83 to 1.22Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.424 · Mean difference (final values): -0.42 · 95% CI -1.45 to 0.61Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
SecondaryChange From Baseline of Mean Spinal Mobility (Chest Expansion) at Week 2, 4, 8 and 12

Chest expansion, measured in centimeters (cm), is defined as the difference in the thoracic circumference during full expiration versus full inspiration. This was measured at the 4th intercostal space. The difference between maximal inspiration and expiration of the two attempts was recorded. The better of the two attempts was used to calculate chest expansion. Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12
Reported as:
Least squares mean · cm
Change From Baseline of Mean Spinal Mobility (Chest Expansion) at Week 2, 4, 8 and 12
cmTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 20.30 ± 0.1440.35 ± 0.143-0.03 ± 0.1440.24 ± 0.144
Week 40.54 ± 0.1640.13 ± 0.1620.13 ± 0.1640.38 ± 0.165
Week 80.52 ± 0.1780.35 ± 0.1780.15 ± 0.1820.13 ± 0.181
Week 120.69 ± 0.1870.49 ± 0.1870.13 ± 0.1900.31 ± 0.193
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.785 · Mean difference (final values): 0.06 · 95% CI -0.34 to 0.46Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.605 · Mean difference (final values): 0.11 · 95% CI -0.30 to 0.51Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.175 · Mean difference (final values): -0.28 · 95% CI -0.68 to 0.12Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.482 · Mean difference (final values): 0.16 · 95% CI -0.29 to 0.62Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.288 · Mean difference (final values): -0.25 · 95% CI -0.70 to 0.21Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.278 · Mean difference (final values): -0.25 · 95% CI -0.71 to 0.21Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.134 · Mean difference (final values): 0.38 · 95% CI -0.12 to 0.88Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.397 · Mean difference (final values): 0.22 · 95% CI -0.29 to 0.72Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.964 · Mean difference (final values): 0.01 · 95% CI -0.50 to 0.52Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.155 · Mean difference (final values): 0.38 · 95% CI -0.15 to 0.91Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.491 · Mean difference (final values): 0.19 · 95% CI -0.34 to 0.72Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.515 · Mean difference (final values): -0.18 · 95% CI -0.71 to 0.36Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
SecondaryChange From Baseline to Week 12 in Short-Form-36 Health Survey (SF-36) Physical and Mental Health Scores at Week 12

SF-36 is a standardized survey evaluating 8 aspects of functional health and wellbeing: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (0=no functioning, 100=highest level of functioning). Missing data at Week 12 were imputed by LOCF if data at an early visit (discontinuation visit) were available.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline to Week 12 in Short-Form-36 Health Survey (SF-36) Physical and Mental Health Scores at Week 12
Units on a scaleTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 12 Physical Health Score6.34 ± 0.9236.49 ± 0.9147.05 ± 0.9432.69 ± 0.932
Week 12 Mental Health Score2.08 ± 1.3064.15 ± 1.2943.71 ± 1.3362.41 ± 1.318
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · ANCOVA · p = 0.006 · Mean difference (final values): 3.65 · 95% CI 1.06 to 6.24ANCOVA model includes fixed effects for treatment group and baseline value as a covariate.
  • Tofacitinib 5 mg BID vs Placebo BID · ANCOVA · p = 0.004 · Mean difference (final values): 3.80 · 95% CI 1.23 to 6.37ANCOVA model includes fixed effects for treatment group and baseline value as a covariate.
  • Tofacitinib 10 mg BID vs Placebo BID · ANCOVA · p = 0.001 · Mean difference (final values): 4.36 · 95% CI 1.74 to 6.98ANCOVA model includes fixed effects for treatment group and baseline value as a covariate.
  • Tofacitinib 2 mg BID vs Placebo BID · ANCOVA · p = 0.857 · Mean difference (final values): -0.34 · 95% CI -4.00 to 3.33ANCOVA model includes fixed effects for treatment group and baseline value as a covariate.
  • Tofacitinib 5 mg BID vs Placebo BID · ANCOVA · p = 0.350 · Mean difference (final values): 1.73 · 95% CI -1.91 to 5.37ANCOVA model includes fixed effects for treatment group and baseline value as a covariate.
  • Tofacitinib 10 mg BID vs Placebo BID · ANCOVA · p = 0.490 · Mean difference (final values): 1.30 · 95% CI -2.40 to 5.00ANCOVA model includes fixed effects for treatment group and baseline value as a covariate.
SecondaryChange From Baseline in EuroQol EQ-5D Health State Profile (EQ-5D) Utility Score at Week 12

EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of single utility score. Health state profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain/discomfort and anxiety/depression; Scale range 1 to 3 (1=better health state \[no problems\], 3=worst health state \[confined to bed\]).

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in EuroQol EQ-5D Health State Profile (EQ-5D) Utility Score at Week 12
Units on a scaleTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Change From Baseline in EuroQol EQ-5D Health State Profile (EQ-5D) Utility Score at Week 120.17 ± 0.0340.16 ± 0.0340.22 ± 0.0350.10 ± 0.034
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · ANCOVA · p = 0.125 · Mean difference (final values): 0.07 · 95% CI -0.02 to 0.17ANCOVA model includes fixed effects for treatment group and baseline value as a covariate.
  • Tofacitinib 5 mg BID vs Placebo BID · ANCOVA · p = 0.207 · Mean difference (final values): 0.06 · 95% CI -0.03 to 0.16ANCOVA model includes fixed effects for treatment group and baseline value as a covariate.
  • Tofacitinib 10 mg BID vs Placebo BID · ANCOVA · p = 0.013 · Mean difference (final values): 0.12 · 95% CI 0.03 to 0.22ANCOVA model includes fixed effects for treatment group and baseline value as a covariate.
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Weeks 2, 4, 8 and 12

FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). Larger the participant's response to the questions (with the exception of 2 negatively stated), greater was the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).

Time frame:
Baseline, Week 2, Week 4, Week 8, Week 12
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Weeks 2, 4, 8 and 12
Units on a scaleTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Week 23.62 ± 0.8711.97 ± 0.8712.17 ± 0.8751.90 ± 0.872
Week 44.25 ± 0.9313.67 ± 0.9272.80 ± 0.9372.71 ± 0.938
Week 84.54 ± 1.0394.81 ± 1.0394.19 ± 1.0612.85 ± 1.053
Week 124.74 ± 1.1457.03 ± 1.1457.58 ± 1.1663.08 ± 1.178
Statistical analysis
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.163 · Mean difference (final values): 1.72 · 95% CI -0.71 to 4.15Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.955 · Mean difference (final values): 0.07 · 95% CI -2.36 to 2.50Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.826 · Mean difference (final values): 0.27 · 95% CI -2.17 to 2.71Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.246 · Mean difference (final values): 1.54 · 95% CI -1.07 to 4.14Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.467 · Mean difference (final values): 0.96 · 95% CI -1.64 to 3.56Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.948 · Mean difference (final values): 0.09 · 95% CI -2.53 to 2.70Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.255 · Mean difference (final values): 1.69 · 95% CI -1.23 to 4.61Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.187 · Mean difference (final values): 1.96 · 95% CI -0.96 to 4.87Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.373 · Mean difference (final values): 1.34 · 95% CI -1.62 to 4.29Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 2 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.313 · Mean difference (final values): 1.66 · 95% CI -1.58 to 4.90Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 5 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.017 · Mean difference (final values): 3.95 · 95% CI 0.71 to 7.19Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix
  • Tofacitinib 10 mg BID vs Placebo BID · Mixed Models Analysis · p = 0.007 · Mean difference (final values): 4.51 · 95% CI 1.23 to 7.78Includes fixed effects of treatment group, visit, and treatment-group by-visit interaction and baseline value, using an unstructured covariance matrix

Adverse events

Collected over From informed consent through and including 28 calendar days after the last administration of the investigational product.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tofacitinib 2 mg BID—0/52 (0%)15/52 (28.8%)
Tofacitinib 5 mg BID—1/52 (1.9%)10/52 (19.2%)
Tofacitinib 10 mg BID—1/52 (1.9%)13/52 (25%)
Placebo BID—2/51 (3.9%)14/51 (27.5%)
Most frequent serious events
Most frequent serious events
EventTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
Foetal deathPregnancy, puerperium and perinatal conditions0/180/130/141/19
Uterine spasmReproductive system and breast disorders0/180/130/141/19
Vaginal haemorrhageReproductive system and breast disorders0/180/130/141/19
VertigoEar and labyrinth disorders0/520/520/521/51
IridocyclitisEye disorders0/521/520/520/51
Tendon injuryInjury, poisoning and procedural complications0/520/521/520/51
Most frequent other events
Showing 10 of 18
Most frequent other events
EventTofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BID
NasopharyngitisInfections and infestations4/524/522/523/51
Upper respiratory tract infectionInfections and infestations4/520/523/521/51
Abdominal pain upperGastrointestinal disorders3/520/522/521/51
Vulvovaginal mycotic infectionInfections and infestations1/180/130/140/19
Vaginitis bacterialInfections and infestations0/180/130/141/19
PregnancyPregnancy, puerperium and perinatal conditions0/180/130/141/19
BronchitisInfections and infestations0/520/521/522/51
DizzinessNervous system disorders0/520/520/522/51
RashSkin and subcutaneous tissue disorders1/520/520/522/51
DiarrhoeaGastrointestinal disorders2/521/520/521/51

Baseline characteristics

Safety population - included participants who received at least 1 dose of study medication

Age, Continuous
Age, Continuous(Years)Tofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BIDTotal
Age41.8 ± 12.341.2 ± 10.341.6 ± 12.241.9 ± 12.941.6 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Tofacitinib 2 mg BIDTofacitinib 5 mg BIDTofacitinib 10 mg BIDPlacebo BIDTotal
Female1813141964
Male34393832143
08

Study locations

67 sites
  • Desert Medical Imaging
    Indian Wells, California 92210, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Arthritis & Rheumatology Associates
    Clearwater, Florida 33756, United States
  • Millennium Research
    Ormond Beach, Florida 32174, United States
  • Southwest Florida Clinical Research Center
    Tampa, Florida 33609, United States
  • Covance Central Laboratory Services,Inc
    Indianapolis, Indiana 46214, United States
  • Klein & Associates, M.D., P.A.
    Hagerstown, Maryland 21740, United States
  • Progressive Radiology
    Hagerstown, Maryland 21740, United States
  • Advanced Medical Imaging (MRI center)
    Lincoln, Nebraska 68506, United States
  • Arthritis Center of Nebraska (X-ray center)
    Lincoln, Nebraska 68516, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • Charlotte Radiology/ Carolina Imaging Services
    Ballantyne, North Carolina 28277, United States
  • Joint and Muscle Research Institute
    Charlotte, North Carolina 28204, United States
  • Presbyterian Imaging
    Charlotte, North Carolina 28207, United States
  • Paramount Medical Research & Consulting, LLC
    Middleburg Heights, Ohio 44130, United States
  • Premier Physicians Centers
    Westlake, Ohio 44145, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Clinical Research Center of Reading, LLC
    Wyomissing, Pennsylvania 19610, United States
  • Investigational Drug Service
    Seatle, Washington 98122, United States
  • Seattle Rheumatology Associates
    Seattle, Washington 98122, United States
  • Arthritis Northwest, PLLC
    Spokane, Washington 99204, United States
  • Institut de Rhumatologie de Montreal
    Montreal, Quebec H2L 1S6, Canada
  • G.R.M.O. Inc
    Quebec, G1V 3M7, Canada
  • Artroscan s.r.o.
    Ostrava, 722 00, Czech Republic
  • Mediscan Group s.r.o.
    Praha 11- Chodov, 14800, Czech Republic
  • Revmatologicky ustav
    Praha 2, 128 50, Czech Republic
  • Revmatologicka ambulance
    Praha 4, 140 00, Czech Republic
  • Medical Plus
    Uherske Hradiste, 68601, Czech Republic
  • Charité Universitaetsmedizin Berlin
    Berlin, 12203, Germany
  • Praxis fuer klinische Studien
    Hamburg, 22415, Germany
  • Gemeinschaftspraxis Dres. von Hinueber / Demary
    Hildesheim, 31134, Germany
  • Immunologisches Zentrum Vogelsang-Gommern GmbH
    Vogelsang-Gommern, 39245, Germany
  • Orszagos Reumatologiai es Fiziotherapias Intezet II. Reumatologiai Osztaly
    Budapest, 1023, Hungary
  • Qualiclinic Kft
    Budapest, 1036, Hungary
  • Synexus Magyarorszag Kft. - Synexus Hungary Clinical Research Centre
    Budapest, 1036, Hungary
  • Dr. Rethy Pál Korhaz es Rendelointezet, Reumatologia
    Békéscsaba, 5600, Hungary
  • Debreceni Egyetem Orvos- és Egészségtudományi Centrum
    Debrecen, 4032, Hungary
  • CRU Hungary Kft.
    Szikszó, 3800, Hungary
  • Csolnoky Ferenc Korhaz Reumatologiai Osztaly
    Veszprem, H-8200, Hungary
  • Chonnam National University Hospital
    Gwangju, 501-757, Korea, Republic of
  • INHA University Hospital
    Incheon, 400-711, Korea, Republic of
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
  • Ajou University Hospital
    Suwon, 443-721, Korea, Republic of
  • NZOZ Lecznica MAK-MED s.c.
    Nadarzyn, Mazowieckie 05-830, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej Centrum Osteoporozy i Chorob Kostno-Stawowych
    Bialystok, 15- 879, Poland
  • Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy
    Bydgoszcz, 85-168, Poland
  • Centrum Kliniczno-Badawcze J. Brzezicki, B. Gornikiewicz-Brzezicka Lekarze Spolka Partnerska
    Elblag, 82-300, Poland
  • Medica Pro Familia Sp. z o.o. S.K.A. Oddzial Katowice
    Katowice, 40-954, Poland
  • Malopolskie Centrum Medyczne S.C.
    Krakow, 30-510, Poland
  • Zespol Poradni Specjalistycznych Reumed Filia Onyksowa
    Lublin, 20-582, Poland
  • Twoja Przychodnia - Centrum Medyczne Nowa Sol
    Nowa Sol, 67-100, Poland
  • NZOZ Nasz Lekarz Praktyka Grupowa Lekarzy Rodzinnych z Przychodnia Specjalistyczna w Toruniu
    Torun, 87-100, Poland
  • SBEI HPE Ural State Medical University of MoH of RF based on Municipal Budgetary Institution
    Ekaterinburg, 620149, Russian Federation
  • Federal State Budgetary Institution
    Moscow, 115522, Russian Federation
  • OOO AVA-PETER "Scandinavia clinic"
    Saint-Petersburg, 191014, Russian Federation
  • Saint-Petersburg State Budgetary Healthcare Institution
    Sestroretsk, 197706, Russian Federation
  • Hospital Clinico Universitario Santiago de Compostela
    Santiago de Compostela, A Coruna 15706, Spain
  • Hospital Universitari de Bellvitge
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, Cantabria 39008, Spain
  • Complexo Hospitalario Universitario A Coruna
    A Coruna, 15006, Spain
  • Hospital Universitario Reina Sofia
    Cordoba, 14004, Spain
  • Hospital Universitario De La Paz
    Madrid, 28046, Spain
  • Corporacio Sanitaria Parc Tauli
    Sabadell, 08208, Spain
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, 80756, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, 40201, Taiwan
  • China medical university hospital
    Taichung, 40447, Taiwan
09

References and documents

Publications

  • Cella D, Lenderking WR, Chongpinitchai P, Bushmakin AG, Dina O, Wang L, Cappelleri JC, Navarro-Compan V. Functional Assessment of Chronic Illness Therapy-Fatigue is a reliable and valid measure in patients with active ankylosing spondylitis. J Patient Rep Outcomes. 2022 Sep 23;6(1):100. doi: 10.1186/s41687-022-00508-0. PubMed 36138330 ↗
  • van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, Li D, Menon S, Kanik KS. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017 Aug;76(8):1340-1347. doi: 10.1136/annrheumdis-2016-210322. Epub 2017 Jan 27. PubMed 28130206 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2013
First posted
Feb 8, 2013
Start
Apr 2013
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
Jun 10, 2016
Last update
Jun 10, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01786668
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 8, 2013
Start date
Apr 2013
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
Jun 10, 2016
Last update
Jun 10, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tofacitinib

Start the discussion